| Age | |||||
---|---|---|---|---|---|---|
18–29 n = 22,270 | 30–39 n = 24,314 | 40–49 n = 17,819 | 50–59 n = 19,184 | 60–64 n = 5050 | Total n = 88,637 | |
Race n (%) | ||||||
 Non-Hispanic White | 16,327 (73.3) | 15,697*** (64.6) | 6237*** (35.0) | 4001*** (20.9) | 1019*** (20.2) | 43,281 (48.8) |
 Non-Hispanic Black | 1577 (7.1) | 1951*** (8.02) | 3074*** (17.3) | 5475*** (28.5) | 1696*** (33.6) | 13,773 (15.5) |
 Latinx | 1688 (7.6) | 3792*** (15.6) | 5830*** (32.7) | 6926*** (36.1) | 1674*** (33.2) | 19,910 (22.5) |
 Other | 1282 (5.8) | 1894*** (7.8) | 2107*** (11.8) | 2366*** (12.3) | 586*** (11.6) | 8235 (9.3) |
 Unknown | 1396 (6.3) | 980*** (4.0) | 571*** (3.2) | 416*** (2.2) | 75*** (1.5) | 3438 (3.9) |
Gender n (%) | ||||||
 Female | 8874 (39.9) | 9429* (38.8) | 5766*** (32.4) | 6199*** (32.3) | 1611*** (31.9) | 31,879 (36.0) |
 Male | 13,396 (60.2) | 14,885** (61.2) | 12,053*** (67.6) | 12,985*** (67.7) | 3439*** (68.1) | 56,758 (64.0) |
Location n (%) | ||||||
 New York City (NYC) | 4502 (20.2) | 7428*** (30.6) | 10,562*** (59.3) | 14,385*** (35.0) | 4023*** (80.0) | 40,900 (46.1) |
 Outside NYC | 17,768 (79.8) | 16,886*** (69.5) | 7257*** (40.7) | 4799*** (25.0) | 1027*** (20.3) | 47,737 (53.9) |
Mean Medicaid eligibility months, (standard deviation) | 10.6 (2.5) | 10.9*** (2.3) | 11.1*** (2.1) | 11.4*** (1.8) | 11.5*** (1.6) | 11.0 (2.2) |
Treatment Utilization n (%) | ||||||
 Medication-Assisted Treatment (MAT) | 10,948 (49.2) | 15,172*** (62.4) | 12,181*** (68.4) | 14,363*** (74.9) | 4262*** (84.4) | 56,926 (64.2) |
 -Methadone | 3950 (17.7) | 7209*** (29.7) | 8554*** (48.0) | 12,034*** (62.7) | 3868*** (76.6) | 35,615 (40.2) |
 -Naltrexone | 656 (3.0) | 584*** (2.4) | 374*** (2.1) | 278*** (1.5) | 37*** (0.7) | 1929 (2.2) |
 -Buprenorphine | 6342 (28.5) | 7379*** (30.4) | 3253*** (18.3) | 2051*** (10.7) | 357*** (7.1) | 19,382 (21.9) |
Non-Medication Treatment | 11,322 (50.8) | 9142*** (37.6) | 5638*** (31.6) | 4821*** (25.1) | 788*** (15.6) | 31,711 (35.8) |